Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag202 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Ajay Major und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, University of Colorado School of Medicine, Aurora, CO 80045, United States. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antibodies, Bispecific, Lymphoma, Follicular, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Genentech, Inc.
Abstract (Originalsprache)
Background
Several bispecific antibodies (BsAbs), including mosunetuzumab, glofitamab, and epcoritamab, are approved for non-Hodgkin lymphoma (NHL). However, real-world patient-centered data evaluating treatment-related time burden and preferences are lacking.
Methods
We conducted an online survey of 120 patients with relapsed/refractory follicular lymphoma (FL; N = 60) and diffuse large B-cell lymphoma (DLBCL; N = 60) receiving BsAbs. Participants reported all-cause healthcare visits and time spent on cancer-related healthcare resource utilization over the past 30 days, including travel, treatment administration, recovery, and impact on daily activities. Participants also evaluated two hypothetical treatment profiles to assess preference for fixed-duration versus treat-to-progression therapy.
Results
Participants with FL reported a mean of 2.5 healthcare visits in the past 30 days, with significantly fewer visits for mosunetuzumab versus epcoritamab (1.7 vs 3.3, respectively; P < .01). In DLBCL, the mean was 2.6 visits, with fewer visits for glofitamab versus epcoritamab (2.2 vs 3.0; P =.01). Although epcoritamab visits were shorter in FL, more frequent visits and longer recovery time resulted in significantly lower monthly time burden with mosunetuzumab versus epcoritamab (31.2 vs 61.9 hours; P < .05). Similarly, monthly time burden was also lower with glofitamab than epcoritamab in DLBCL (43.0 vs 87.7 hours; P < .05). Most participants reported little to moderate impact on daily activities. Across treatment groups, ≥92% preferred a hypothetical fixed-duration regimen over a treat-to-progression therapy.
Conclusion
Our real-world data, including novel aspects of time toxicity, demonstrate clinically meaningful differences in time burden associated with BsAbs and emphasize the importance of incorporating patient convenience and preference into shared decision-making in NHL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, University of Colorado School of Medicine, Aurora, CO 80045, United States.
- Genentech, Inc., South San Francisco, CA 94080, United States.
- Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ 85054, United States.
- Department of Medicine, Divison of Hematology and Oncology, Fred Hutchinson Cancer Center and University of Washington, Seattle, WA 98109, United States.
- Department of Hematology and Oncology, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX 78229, United States.
- Department of Medicine, Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin, Carbone Cancer Center, Madison, WI 53792, United States.
ORCID-Profile: Ajay Major, Mengyang Di
Förderung
- NCI NIH HHS
- Genentech, Inc
Zitieren
APA
Major, A., Ma, E., Masaquel, A., Tsang, M., Di, M., Kaur, S., Pophali, P., Werner, S., Bungay, R., Latrémouille-Viau, D., Guerin, A., Reyes, C., Wu, M., Cassoli, L., & Torka, P. (2026). Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. The Oncologist. https://doi.org/10.1093/oncolo/oyag202
Vancouver
Major A, Ma E, Masaquel A, Tsang M, Di M, Kaur S, et al. Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. The Oncologist. 2026. doi:10.1093/oncolo/oyag202
BibTeX
@article{Major2026,
author = {Major, Ajay and Ma, Esprit and Masaquel, Anthony and Tsang, Mazie and Di, Mengyang and Kaur, Supreet and Pophali, Priyanka and Werner, Sally and Bungay, Rebecca and Latrémouille-Viau, Dominick and Guerin, Annie and Reyes, Carolina and Wu, Mei and Cassoli, Lourenia and Torka, Pallawi},
title = {Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag202}
}
EUVIMED